Amgen, Eli Lilly to scale up manufacturing of COVID-19 antibody therapies

By The Science Advisory Board staff writers

September 17, 2020 -- Eli Lilly and Amgen will collaborate on global antibody manufacturing to significantly increase the supply capacity of Lilly's potential COVID-19 therapies.

Currently, Lilly is evaluating several potential neutralizing antibodies, such as LY-CoV-555, for the prevention and/or treatment of COVID-19 as monotherapies or in combination. Through the collaboration, the companies will have the ability to quickly scale up production of antibody therapies that are successful in clinical testing and receive regulatory approval.

The companies hope to be able to produce millions of doses in 2021.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.